SMTL ID : 7rfw.1

Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.73 Å

Oligo State

homo-dimer

Ligands

2 x 4WI: (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide(Non-covalent)

4WI.1: 22 residues within 4Å: Chain A: H.42, M.50, Y.55, F.141, L.142, N.143, G.144, S.145, C.146, H.164, H.165, M.166, E.167, L.168, P.169, H.173, D.188, R.189, Q.190, T.191, Q.193 Chain B: S.2 13 PLIP interactions: 13 interactions with chain A Hydrophobic interactions: A:H.42, A:M.166, A:E.167 Hydrogen bonds: A:G.144, A:S.145, A:C.146, A:H.165, A:E.167, A:E.167, A:E.167, A:T.191 pi-Stacking: A:H.42 Halogen bonds: A:Q.193 4WI.2: 22 residues within 4Å: Chain A: S.2 Chain B: H.42, M.50, Y.55, F.141, L.142, N.143, G.144, S.145, C.146, H.164, H.165, M.166, E.167, L.168, P.169, H.173, D.188, R.189, Q.190, T.191, Q.193 14 PLIP interactions: 14 interactions with chain B Hydrophobic interactions: B:H.42, B:M.166, B:E.167 Hydrogen bonds: B:G.144, B:S.145, B:C.146, B:H.165, B:E.167, B:E.167, B:E.167, B:E.167, B:T.191 pi-Stacking: B:H.42 Halogen bonds: B:Q.193

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Owen, D.R. et al., An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science (2021)

Release Date

2021-11-10

Peptides

3C-like proteinase: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
A

3C-like proteinase

Related Entries With Identical Sequence